Single-Cell RNA Sequencing of Peripheral Blood Mononuclear Cells Identifies Na⁺/K⁺-ATPase Inhibitors and Immune Modulators as Drug Repurposing Candidates for Type 1 Diabetes Mellitus

Read full text Summarise with VIRAT
Authors: Glen Charles Ritschel, Claude
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Single-cell RNA sequencing (scRNA-seq) was applied to peripheral blood mononuclear cells (PBMCs) from 6 Type 1 Diabetes Mellitus (T1DM) patients, 3 healthy controls, and 3 pre-diabetic donors (GEO accession GSE221297; n=60,000 cells post-QC). Unsupervised Leiden clustering identified 23 cell populations; monocyte clusters 11, 12, 13, and 16 were selected based on co-expression of classical monocyte markers (CD14, LYZ, S100A8, S100A9, CSF1R, VCAN), non-classical markers (FCGR3A, MS4A7, CX3CR1), and T1DM-relevant IFN-stimulated genes (SIGLEC1, IFI30, IFIT1, MX1). Cluster 16 exhibited a strong SIGLEC-1+ IFN-activated monocyte signature consistent with a known T1DM disease-activity biomarker. Wilcoxon rank-sum differential expression analysis identified 2,749 genes significantly upregulated in T1DM versus control monocytes. LINCS L1000 computational drug repurposing yielded 200 NOVEL_ALL candidates scored by composite formula (N_targets × 10 + max_pChEMBL). Top candidates are dominated by Na+/K+-ATPase inhibitors (digitoxigenin, ouabain, bufalin, cinobufagin, cymarin, sarmentogenin), with additional candidates including anisomycin, cephaeline, narciclasine, and BNTX. A cross-disease signal was confirmed for QL-XII-47 (MELK/FLT3 inhibitor), previously identified across psoriasis, IBD, irAE, WAT browning, and GBM pipelines. These findings implicate Na+/K+-ATPase signaling as a novel therapeutic axis in T1DM monocyte pathobiology.

Fields of Study & Subjects

Diabetes and associated disorders Single-cell and spatial transcriptomics Computational Drug Discovery Methods

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
28 March 2026
Language
EN
Document type
Preprint